CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition ...

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2025.